Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

NCT04416984 is registered in ClinicalTrials.gov with Allogene Therapeutics as lead sponsor.

NCT NCT04416984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04416984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Lead sponsor
Allogene Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 21, 2020
Completion date
May 31, 2029
Enrollment
160 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory large b cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, relapsed or refractory small lymphocytic lymphoma